Evidence map›Paper›PMID 33545739›Full record

SynthesisThe Cochrane database of systematic reviews2021

Skin care interventions in infants for preventing eczema and food allergy.

Maeve M Kelleher, Suzie Cro, Victoria Cornelius, Karin C Lodrup Carlsen, Håvard O Skjerven, Eva M Rehbinder, Adrian J Lowe, Eishika Dissanayake, Naoki Shimojo, Kaori Yonezawa and 18 more

Open access · bronzeAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in The Cochrane database of systematic reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 5 pooled it
24.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 5 syntheses or guidelines pooled it, 97 citations in OpenAlex.

  1. Skin care interventions in infants for preventing eczema and food allergy.The Cochrane database of systematic reviews · 2022
    Pooled it
  2. Pooled it
  3. Individual participant data meta-analysis versus aggregate data meta-analysis: A case study in eczema and food allergy prevention.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2022
    Pooled it
  4. Topical emollient for preventing infection in preterm infants.The Cochrane database of systematic reviews · 2021
    Pooled it
  5. Skin care interventions in infants for preventing eczema and food allergy.The Cochrane database of systematic reviews · 2021
    Pooled it
  6. Emollient application from birth to prevent eczema in high-risk children: the BEEP RCT.Health technology assessment (Winchester, England) · 2024
    Trial
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Review
  12. Review
  13. The age of eczema onset and multiple food allergies.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2026
    Article
  14. Prevention of Atopic Dermatitis: What Are We Missing?Allergy, asthma & immunology research · 2025
    Review
  15. Article
  16. Review
  17. Genetic and Immunological Pathogenesis of Atopic Dermatitis.The Journal of investigative dermatology · 2024
    Review
  18. Article
  19. Article
  20. Environmental Influences on Atopic Eczema.Journal of environmental science and public health · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors at 17 institutions in 7 countries.

Maeve M KelleherNational Heart & Lung Institute, Section of Inflammation and Repair, Imperial College London, London, UK.
Suzie CroImperial Clinical Trials Unit, Imperial College London, London, UK.
Victoria CorneliusImperial Clinical Trials Unit, Imperial College London, London, UK.
Karin C Lodrup CarlsenDivision of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.
Håvard O SkjervenDivision of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.
Eva M RehbinderFaculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Adrian J LoweAllergy and Lung Health Unit, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia.
Eishika DissanayakeDepartment of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Naoki ShimojoCenter for Preventive Medical Sciences, Chiba University, Chiba, Japan.
Kaori YonezawaDepartment of Midwifery and Women's Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yukihiro OhyaAllergy Center, National Center for Child Health and Development, Tokyo, Japan.
Kiwako Yamamoto-HanadaAllergy Center, National Center for Child Health and Development, Tokyo, Japan.
Kumiko MoritaDepartment of Pediatrics, Keio University School of Medicine, Tokyo, Japan.
Emma AxonCentre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK.
Christian SurberDepartment of Dermatology, University Hospital Zurich, Zurich, Switzerland.
Michael CorkSheffield Dermatology Research, Department of Infection, Immunity & Cardiovascular Disease, The University of Sheffield, Sheffield, UK.
Alison CookeDivision of Nursing, Midwifery and Social Work, School of Health Sciences, The University of Manchester, Manchester, UK.
Lien TranImperial Clinical Trials Unit, Imperial College London, London, UK.
Eleanor Van VogtImperial Clinical Trials Unit, Imperial College London, London, UK.
Jochen SchmittCenter for Evidence-Based Healthcare, Faculty of Medicine Carl Gustav Carus, Technischen Universität (TU) Dresden, Dresden, Germany.
Stephan WeidingerDepartment of Dermatology and Allergy, University Hospital Scheswig-Holstein, Kiel, Germany.
Danielle McClanahanDepartment of Dermatology, Oregon Health & Science University, Portland, Oregon, USA.
Eric SimpsonDepartment of Dermatology, Oregon Health & Science University, Portland, Oregon, USA.
Lelia DuleyNottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.
Lisa M AskieNHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.
Joanne R ChalmersCentre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK.
Hywel C WilliamsCentre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK.
Robert J BoyleNational Heart & Lung Institute, Section of Inflammation and Repair, Imperial College London, London, UK.
Imperial College London · GBUniversity of Nottingham · GBNational Center For Child Health and Development · JPOregon Health & Science University · USOslo University Hospital · NOChiba University · JPKeio University · JPNational Health and Medical Research Council · AUThe University of Tokyo · JPUniversity Hospital Carl Gustav Carus · DEUniversity Hospital of Zurich · CHUniversity Hospital Schleswig-Holstein · DEUniversity of Manchester · GBUniversity of Melbourne · AUUniversity of Oslo · NOUniversity of Sheffield · GBUniversity of Wisconsin–Madison · US

Funding

Department of Health 12/67/12Department of Health PB-PG-0317-20028
6 · The paper itself

Abstract

backgroundEczema and food allergy are common health conditions that usually begin in early childhood and often occur together in the same people. They can be associated with an impaired skin barrier in early infancy. It is unclear whether trying to prevent or reverse an impaired skin barrier soon after birth is effective in preventing eczema or food allergy.

objectivesPrimary objective To assess effects of skin care interventions, such as emollients, for primary prevention of eczema and food allergy in infants Secondary objective To identify features of study populations such as age, hereditary risk, and adherence to interventions that are associated with the greatest treatment benefit or harm for both eczema and food allergy. SEARCH

methodsWe searched the following databases up to July 2020: Cochrane Skin Specialised Register, CENTRAL, MEDLINE, and Embase. We searched two trials registers and checked reference lists of included studies and relevant systematic reviews for further references to relevant randomised controlled trials (RCTs). We contacted field experts to identify planned trials and to seek information about unpublished or incomplete trials. SELECTION CRITERIA: RCTs of skin care interventions that could potentially enhance skin barrier function, reduce dryness, or reduce subclinical inflammation in healthy term (> 37 weeks) infants (0 to 12 months) without pre-existing diagnosis of eczema, food allergy, or other skin condition were included. Comparison was standard care in the locality or no treatment. Types of skin care interventions included moisturisers/emollients; bathing products; advice regarding reducing soap exposure and bathing frequency; and use of water softeners. No minimum follow-up was required. DATA COLLECTION AND ANALYSIS: This is a prospective individual participant data (IPD) meta-analysis. We used standard Cochrane methodological procedures, and primary analyses used the IPD dataset. Primary outcomes were cumulative incidence of eczema and cumulative incidence of immunoglobulin (Ig)E-mediated food allergy by one to three years, both measured by the closest available time point to two years. Secondary outcomes included adverse events during the intervention period; eczema severity (clinician-assessed); parent report of eczema severity; time to onset of eczema; parent report of immediate food allergy; and allergic sensitisation to food or inhalant allergen. MAIN

resultsThis review identified 33 RCTs, comprising 25,827 participants. A total of 17 studies, randomising 5823 participants, reported information on one or more outcomes specified in this review. Eleven studies randomising 5217 participants, with 10 of these studies providing IPD, were included in one or more meta-analysis (range 2 to 9 studies per individual meta-analysis). Most studies were conducted at children's hospitals. All interventions were compared against no skin care intervention or local standard care. Of the 17 studies that reported our outcomes, 13 assessed emollients. Twenty-five studies, including all those contributing data to meta-analyses, randomised newborns up to age three weeks to receive a skin care intervention or standard infant skin care. Eight of the 11 studies contributing to meta-analyses recruited infants at high risk of developing eczema or food allergy, although definition of high risk varied between studies. Durations of intervention and follow-up ranged from 24 hours to two years. We assessed most of this review's evidence as low certainty or had some concerns of risk of bias. A rating of some concerns was most often due to lack of blinding of outcome assessors or significant missing data, which could have impacted outcome measurement but was judged unlikely to have done so. Evidence for the primary food allergy outcome was rated as high risk of bias due to inclusion of only one trial where findings varied when different assumptions were made about missing data. Skin care interventions during infancy probably do not change risk of eczema by one to two years of age (risk ratio (RR) 1.03, 95% confidence interval (CI) 0.81 to 1.31; moderate-certainty evidence; 3075 participants, 7 trials) nor time to onset of eczema (hazard ratio 0.86, 95% CI 0.65 to 1.14; moderate-certainty evidence; 3349 participants, 9 trials). It is unclear whether skin care interventions during infancy change risk of IgE-mediated food allergy by one to two years of age (RR 2.53, 95% CI 0.99 to 6.47; 996 participants, 1 trial) or allergic sensitisation to a food allergen at age one to two years (RR 0.86, 95% CI 0.28 to 2.69; 1055 participants, 2 trials) due to very low-certainty evidence for these outcomes. Skin care interventions during infancy may slightly increase risk of parent report of immediate reaction to a common food allergen at two years (RR 1.27, 95% CI 1.00 to 1.61; low-certainty evidence; 1171 participants, 1 trial). However, this was only seen for cow's milk, and may be unreliable due to significant over-reporting of cow's milk allergy in infants. Skin care interventions during infancy probably increase risk of skin infection over the intervention period (RR 1.34, 95% CI 1.02 to 1.77; moderate-certainty evidence; 2728 participants, 6 trials) and may increase risk of infant slippage over the intervention period (RR 1.42, 95% CI 0.67 to 2.99; low-certainty evidence; 2538 participants, 4 trials) or stinging/allergic reactions to moisturisers (RR 2.24, 95% 0.67 to 7.43; low-certainty evidence; 343 participants, 4 trials), although confidence intervals for slippages and stinging/allergic reactions are wide and include the possibility of no effect or reduced risk. Preplanned subgroup analyses show that effects of interventions were not influenced by age, duration of intervention, hereditary risk, FLG mutation,  or classification of intervention type for risk of developing eczema. We could not evaluate these effects on risk of food allergy. Evidence was insufficient to show whether adherence to interventions influenced the relationship between skin care interventions and risk of developing eczema or food allergy. AUTHORS'

conclusionsSkin care interventions such as emollients during the first year of life in healthy infants are probably not effective for preventing eczema, and probably increase risk of skin infection. Effects of skin care interventions on risk of food allergy are uncertain. Further work is needed to understand whether different approaches to infant skin care might promote or prevent eczema and to evaluate effects on food allergy based on robust outcome assessments.

Indexed as

BiasEczemaEmollientsFemaleFilaggrin ProteinsFood HypersensitivityHumansHypersensitivity, ImmediateImmunoglobulin EInfantInfant, NewbornMaleMilk HypersensitivitySkin CareSkin Diseases, InfectiousSoapsEmollientsFilaggrin ProteinsFLG protein, humanImmunoglobulin ESoaps

Identifiers

PMID33545739
PMCPMC8094581
OpenAlexW3004645006

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.